A new study conducted by researchers from Augusta University and The University of Texas Health Science Center at Houston has found that cannabidiol (CBD) may serve as a promising, cost-effective treatment for Alzheimer’s disease (AD).
Published in the International Journal of Molecular Sciences, the study suggests that inhaled CBD could help improve cognitive function and reduce the accumulation of amyloid plaques, key markers of Alzheimer’s disease.
The research focused on CBD’s impact on acetylcholine (ACh) production, a neurotransmitter essential for cognitive functions. Additionally, the study examined how CBD influences innate lymphoid cells (ILCs), specifically ILC2s, a subtype of immune cells linked to inflammation. Researchers treated 5xFAD mice, a genetic model for Alzheimer’s, with a broad-spectrum CBD formulation via inhalation over a seven-month period. The treatment resulted in improved cognitive function, reduced senile plaques, and an altered ILC2 profile within the central nervous system.
The study’s abstract notes, “Together, our studies showed that long-term inhalation of CBD improved cognitive function and reduced senile plaques in a murine AD model, effects that were associated with enhanced ACh production and altered ILC2s distribution within the CNS.” These findings underscore the potential of CBD as a non-invasive alternative to traditional Alzheimer’s treatments, which often involve invasive or costly procedures with varying levels of effectiveness.
While these results are promising, the researchers emphasize that further studies are necessary to understand the underlying mechanisms by which CBD may influence Alzheimer’s progression. The study points to CBD’s ability to modify immune cell behavior and neurotransmitter production as a compelling area for future research, with potential implications for therapeutic strategies aimed at managing Alzheimer’s disease.
This study adds to the growing body of evidence supporting CBD’s therapeutic benefits, particularly in the area of neurodegenerative diseases.
More articles from The Marijuana Herald:
